Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas

Inclusion Criteria: * retinal vein occlusion with OCT-diagnosed macular edema with a documented duration of 3 months or less * age over 18 * documented maximal visual acuity of 0,5 ETDRS * voluntary participation in this study as proven by written informed consent * ability to follow study instructions and likely to attend and complete all required visits * pre-menopausal female patients with childbearing potential must use an approved contraceptive method (Pearl index \<1) * pre-menopausal female patients with childbearing potential: a negative serum pregnancy test must be obtained prior to treatment start * ischemic area of more than 5 pupillary distance (PD) in angiography Exclusion Criteria: * subject without legal capacity who is unable to understand the nature, scope, significance and consequences of this clinical trial * patients with known allergy to Ranibizumab or ingredients of the injection solution * treatment in another clinical trial with therapeutic intervention or use of any other investigational medicinal product (IMP) during the trial or within the 30 days before enrolment * known or persistent abuse of medication, drugs or alcohol * women who are pregnant or breast-feeding * failure of laboratory inclusion criteria * diabetic retinopathy * previous anti-VEGF (Lucentis ®, Avastin®, Eylea®) or LASER therapy due to RVO * previous intravitreal steroid therapy * status post excision of the vitreous body * status post intraocular surgery within 3 months before enrolment * established or suspected ocular or periocular infection * evidence of giant cell arteriitis * retinal hemorrhages that seem to prevent a Laser-treatment of ischemic areals within the following 12 weeks * unregulated hypertension above 200/120 mmHg * cerebral vascular occurence or myocardium infarct within 12 months before enrolment * relevant systemic diseases that might be associated with elevated VEGF serum concentration * active malignancies (status post successful treatment of malignancies is no exclusion criterion)